Clinical trials

  • VORASIDENIB for Grade 2 glioma (oligodendroglioma or astrocytoma) — residual or recurrent, IDH1 or IDH2 mutation
  • ETOPOSIDE for Malignant extracranial germ cell tumours
  • Mosunetuzumab for Relapsed/refractory follicular lymphoma | Follicular lymphoma
  • Baricitinib for Juvenile idiopathic arthritis
  • SELPERCATINIB for Non-small cell lung cancer | RET fusion-positive non-small cell lung cancer | Advanced or metastatic non-small cell lung cancer
  • ETRANACOGENE DEZAPARVOVEC for Hemophilia B
  • SODIUM OXYBATE for Cerebral amyloid angiopathy
  • CAPECITABINE for Breast cancer | Metastatic breast cancer
  • RITLECITINIB TOSILATE for Non-segmental vitiligo
  • DARATUMUMAB for Multiple myeloma
  • Trastuzumab deruxtecan for Breast cancer (HER2-low) with brain metastases | Leptomeningeal disease (type II)
  • efanesoctocog alfa for Haemophilia A|Severe haemophilia A